RecruitingNot Applicable

Intermittent Theta-burst Stimulation for Mild Cognitive Impairment

Hong Kong66 participantsStarted 2024-11-01

Plain-language summary

The objectives of this study are to: 1. Evaluating the Impact of iTBS on Cognitive and Physical Functions: The investigators will investigate the efficacy of intermittent theta burst stimulation (iTBS) in patients with mild cognitive impairment (MCI), focusing on its effects on dual-task walking abilities, balance abilities, and cognitive function. 2. Comparing Clinical Efficacy Based on Stimulation Sites: The investigators will compare the clinical efficacy of iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) versus bilateral DLPFC stimulation. This comparison aims to directly examine potential differences in therapeutic outcomes based on the site of stimulation. 3. Investigating Neurophysiological Mechanisms: The investigators plan to elucidate the neurophysiological mechanisms underlying the improvements in cognitive functions and dual-task walking abilities in MCI patients facilitated by iTBS. This will be achieved using fNIRS neuroimaging of brain activity.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged≥65 years; * Patient-reported subjective cognitive decline and the total score of the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) was between 19 and 25; * Intact daily functioning in ADL scales and being independent in daily living, and ability to walk at least for 1 minute independently without an assistive device; * No serious visual or hearing impairment and can complete relevant assessment and testing; * Signed informed consent of patients and their families for iTBS treatment. Exclusion Criteria: * Identified with contraindications in the rTMS screening questionnaire; * Cognitive dysfunction due to craniocerebral trauma or neurological diseases; * Presence of severe physical illnesses such as speech disorders or unstable cardiac arrhythmias; * Currently in a critical condition such as fever, infection, or organ failure; * Significant damage to the left frontal lobe cortex; * Currently taking antidepressants or psychostimulants; * Unstable vital signs or organ failure; * Neuropsychiatric comorbidity or affective disorder that could affect the test results; * Patients with dementia.

What they're measuring

Dual-task cost in cognition (Reaction time)

Timeframe: before the initiation of treatment, after 3 weeks of treatment, 4 weeks after termination of the treatment

Dual-task cost in gait (gait speed)

Timeframe: before the initiation of treatment, after 3 weeks of treatment, 4 weeks after termination of the treatment

Dual-task cost in cognition (Accuracy)

Timeframe: before the initiation of treatment, after 3 weeks of treatment, 4 weeks after termination of the treatment

Trial details

NCT IDNCT06608316

SponsorThe Hong Kong Polytechnic University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-31

View on ClinicalTrials.gov More Mild Cognitive Impairment (MCI) trials

Plain-language summary

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Dual-task cost in cognition (Reaction time)

Timeframe: before the initiation of treatment, after 3 weeks of treatment, 4 weeks after termination of the treatment

Dual-task cost in gait (gait speed)

Timeframe: before the initiation of treatment, after 3 weeks of treatment, 4 weeks after termination of the treatment

Dual-task cost in cognition (Accuracy)

Timeframe: before the initiation of treatment, after 3 weeks of treatment, 4 weeks after termination of the treatment